Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Abscess formation mimicking disease progression, in a patient with metastatic renal cell carcinoma during sunitinib treatment | Michalaki et al. World Journal of Surgical Oncology 2010 8 45 http content 8 1 45 WORLD JOURNAL OF SURGICAL ONCOLOGY CASE REPORT Open Access Abscess formation mimicking disease progression in a patient with metastatic renal cell carcinoma during sunitinib treatment Vasiliki Michalaki 1 Nikolaos Arkadopoulos2 Agathi Kondi-Pafiti3 and Constantine Gennatas1 Abstract Background Renal cell carcinoma RCC represents approximately 3 of all adult cancers and is more common in males. Systemic treatment for RCC has improved following the introduction of tyrosine kinase inhibitors such as sunitinib. The molecular targets of sunitinib are receptor tyrosine kinases RTKs . Moreover sunitinib has an additional anti-angiogenic effect through its inhibition of the vascular endothelial growth factor receptor activation. Case presentation We present a case of intra-abdominal abscess formation mimicking disease progression in a patient with metastatic renal cell carcinoma during sunitinib treatment. Conclusion In the advancing era of molecular therapy of solid tumours sunitinib has demonstrated significant efficacy in the post-cytokine setting treatment of metastatic renal cancer. Concurrently however increasing evidence has emerged to indicate that this class of drugs exert profound immunomodulatory effects on T cells and play major roles in immune tumor surveillance. Background The treatment of advanced RCC is undergoing a paradigm shift with the recent introduction of anti-angiogenic therapy that either directly inhibits vascular endothelial growth factor or disrupts signal transduction favorable to vascular development through multi-kinase inhibitors. Angiogenic inhibitors have been found to increase survival and are approved in advanced renal cell carcinoma 1 2 . Consequently most of these patients will routinely receive tyrosine kinase inhibitors such as suni-tinib. Sunitinib is an orally administered small molecule inhibitor of multiple receptor tyrosine kinases .
